Usona Institute will begin its Phase 3 Clinical Trial investigating psilocybin for Major Depressive Disorder (MDD), the company announced today.

According to a release, the uAspire trial will start with an initial six-week randomized double-blind treatment period. Participants will be monitored for one year to characterize the treatment durability and long-term safety of psilocybin treatment.

Click here to read the full article.